Buy this ASX 200 stock for big returns after 'impressive launch'

Bell Potter is feeling very bullish about this pharma stock.

| More on:
A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are having a positive start to the week.

In afternoon trade, the ASX 200 pharmaceutical stock is up almost 2% to $14.93.

Why is this ASX 200 stock rising?

The catalyst for the rise in Neuren's shares on Monday appears to be a broker note out of Bell Potter.

According to the note, the broker has retained its buy rating and $17.50 price target on the ASX 200 stock.

This implies a potential upside of over 17% for investors over the next 12 months.

What did the broker say?

Bell Potter highlights that the company's commercial partner, ACADIA Pharmaceuticals Inc (NASDAQ: ACAD), has provided guidance for DAYBUE sales in 2023.

As a reminder, DAYBUE is a product developed by Neuren to treat Rett syndrome and licensed to ACADIA.

ACADIA's guidance implies that some major royalty payments will be heading to Neuren. It commented:

Neuren's commercial partner Acadia is guiding to ~US$175m in DAYBUE sales for CY23 after only 8 months on the US market. This impressive launch will translate into large sums of ongoing royalties and one-off sales milestones to NEU.

The rapid uptake of DAYBUE is reflected in the 800 patients on treatment as of 30th September (~18% of the 4,500 currently identified Rett patients). Also promising is that 80% of US patients are now covered by insurers and treatment persistence of ~75-80% after 4 months is higher than the clinical trial setting.

Based on current sales rates, the broker believes that DAYBUE sales will reach US$460 million in FY 2024 and grow further from there. It said:

DAYBUE's implied 4Q23 annualised sales is US$336m at the guidance midpoint, which all but guarantees NEU will receive the first US$50m sales milestone in CY24. We forecast CY24e DAYBUE sales of ~US$460m which would result in NEU receiving US$50m in royalties plus the US$50m sales milestone. Longer-term, as the only approved treatment for Rett patients, we see potential for DAYBUE to ramp up to ~2k US patients after ~5 years, triggering further sales-based milestones and royalties to NEU.

All in all, this product looks set to be a real cash cow for the ASX 200 stock. And, importantly, it's all profit.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Person with a handful of Australian dollar notes, symbolising dividends.
Dividend Investing

Which ASX 200 healthcare share will pay the best dividend yield in FY24?

Healthcare stocks are a traditional defensive play in challenging economic times.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,
Healthcare Shares

Can NIB shares reach $9 by Christmas?

It has been a good few weeks for shareholders. Can the stock keep going?

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Broker Notes

CSL shares up 15% in 5 weeks amid two hedge funds placing opposing bets

Let's see what these funds have to say about CSL shares.

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Healthcare Shares

Why is the Mesoblast share price sinking 25% on Tuesday?

This biotech is being sold off today. But why?

Read more »

Scientist with headache, stress and fatigue with woman, overworked with overtime for science breakthrough. Medical research, scientific innovation and senior female, burnout and migraine in lab.
Healthcare Shares

Why is the Mesoblast share price in a trading halt?

Is Mesoblast raising funds again? Let's find out.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

The CSL share price return tripled the ASX 200 in November

November saw a very healthy return for CSL shares.

Read more »

A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19
Share Market News

Here's why you might have just bought Healius shares

Two of the most popular super funds just loaded up on this healthcare stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Here's why this ASX 200 healthcare stock is roaring 13% higher on Wednesday

This healthcare company is outperforming every other stock within the ASX 200 today.

Read more »